A
$ Value
$0
Shares
100,000
Price
$0
Filed
Jan 8
Insider
Name
Shiferman Gregory L.
Title
SVP and General Counsel
CIK
0002041689
Roles
Officer
Transaction Details
Transaction Date
2026-01-06
Code
A
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
100,000
Footnotes
This stock option was granted pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan. | The vesting commencement date of the option is the grant date. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting upon the one-year anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service as an employee.
Filing Info
Shiferman Gregory L.'s History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-04-01 | VYGR | A | $0 |
| 2026-01-06 | VYGR | A | $0 |
| 2025-07-31 | SAGE | U | — |
| 2025-07-31 | SAGE | D | — |
| 2025-07-31 | SAGE | D | — |
| 2025-07-31 | SAGE | D | — |
| 2025-06-24 | SAGE | F | $728 |
Other Insiders at VYGR (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Sandrock Alfred
President and CEO
|
— | $184K | 2026-04-02 |
|
Jorgensen Nathan D.
Chief Financial Officer
|
— | $18K | 2026-02-24 |
|
Swartz Robin
COO & CBO
|
— | $55K | 2026-02-24 |
|
Carter Todd Alfred
Chief Scientific Officer
|
— | $41K | 2026-02-24 |
|
Ferguson Toby
Chief Medical Officer
|
— | — | 2026-02-06 |
|
Shiferman Gregory L.
SVP and General Counsel
|
— | — | 2026-04-01 |